DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Early Stage / Preclinical Research
Indiana University and Ludwig Maximilian University researchers reported in Molecular Metabolism that removing GLP-1 from triple agonist peptides preserved weight-loss efficacy in preclinical models. The work, funded by founder startup Bluewater Biosciences, positions glucagon-GIP combinations as a potential alternative for patients intolerant to GLP-1 gastrointestinal effects.
Clinical Considerations
- Triple agonists combining GLP-1, glucagon, and GIP showed weight loss persisted in rodents and monkeys after GLP-1 removal across three evaluation approaches
- Researchers describe GLP-1 as “camouflaging” the contribution of glucagon and GIP, reframing assumptions about which hormone drives appetite suppression
- Investigators are dual-affiliated with funder Bluewater Biosciences, a disclosure relevant to interpreting framing language
- No human data exist; the program’s next phase will assess candidates in patients with obesity
Practice Applications
- Recognize this as preclinical proof-of-concept, not a near-term prescribing alternative
- Avoid discussing as an available option when patients raise GLP-1 tolerability concerns
- Monitor for early-phase human trial readouts before clinical relevance shifts
- Interpret patient questions about “GLP-1 alternatives” as continued GLP-1 counseling opportunities
More on GLP-1s
